Introduction
Type 2 Diabetes Mellitus (T2DM) is a complex metabolic disease characterized by insulin resistance and β-cell dysfunction. While traditionally managed through glycemic control, recent research highlights the significant role of neuroendocrine disorders in the progression of the disease. Jiao-Tai-Wan (JTW), a traditional Chinese medicine formula composed of Rhizoma Coptidis and Cortex Cinnamomi, has shown promise in treating T2DM, yet its underlying mechanisms remain poorly understood. This study investigates whether JTW exerts its hypoglycemic and lipid-lowering effects by rebalancing neurotransmitter distribution across various tissues.
Methods
The researchers employed a high-fat diet and streptozotocin-induced T2DM rat model. Rats were treated with JTW for four weeks, with metformin used as a positive control. The study utilized a multi-faceted analytical approach:
Neurotransmitter Profiling
To map the distribution of key neurotransmitters, the team used Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS). This allowed for the precise quantification of serotonin (5-HT), epinephrine (E), norepinephrine (NE), dopamine (DA), and γ-aminobutyric acid (GABA) across the brain, heart, liver, kidney, adrenal glands, intestine, blood, and urine.
Molecular Analysis of Transporters
To understand the regulation of these neurotransmitters, the expression of their respective transporters—SERT, DAT, NET, and GAT-1—was analyzed using quantitative Real-Time PCR (qRT-PCR) and Western Blotting. These "pumps" are critical for maintaining neurotransmitter homeostasis by facilitating their reuptake into cells.
Results
Metabolic Improvements
JTW treatment significantly improved glucose homeostasis and insulin sensitivity, as evidenced by reduced fasting blood glucose and HOMA-IR scores. Furthermore, JTW ameliorated lipid metabolism disorders, reducing serum triglycerides and LDL-C while increasing HDL-C. Pathological examinations also showed reduced fat accumulation and structural damage in the liver and kidneys.
Rebalancing the Neuroendocrine System
The study revealed that T2DM causes a systemic imbalance in neurotransmitter levels. For instance, 5-HT levels were significantly lower in the brain but higher in the adrenal glands and blood of diabetic rats. JTW treatment effectively reversed these trends, shifting neurotransmitter concentrations back toward healthy levels.
Regulation of Transporter Expression
Mechanistically, JTW was found to modulate the expression of neurotransmitter transporters in the brain and kidney. In T2DM rats, the mRNA and protein levels of SERT, DAT, and GAT-1 were significantly elevated, while NET expression was decreased. JTW treatment successfully downregulated SERT, DAT, and GAT-1 and upregulated NET, suggesting that its therapeutic effect is mediated through the restoration of transporter-driven neurotransmitter homeostasis.
Conclusion
This research provides a novel neuroendocrine perspective on the efficacy of Jiao-Tai-Wan in treating T2DM. By targeting the "pumps" that regulate neurotransmitter distribution, JTW addresses the systemic metabolic chaos associated with diabetes. While further studies are needed to identify the specific active compounds within JTW, these findings highlight the potential of TCM formulas to treat complex metabolic diseases through multi-target regulation.
Reference: Chen, J., et al. (2021). Jiao-Tai-Wan Ameliorates the Insulin Resistance and Lipid Metabolism in T2DM Rats by Regulating Neurotransmitters. Research Square (Preprint). DOI: 10.21203/rs.3.rs-857847/v1
Summary updated